ClinicalTrials.gg
RecruitingNCT05202678Updated Jan 31, 2025

RECONFIRM - Study of AGN1 LOEP in Patients with Osteoporosis

An interventional study of AGN1 LOEP in Osteoporosis, sponsored by AgNovos Healthcare, LLC. Recruiting at 1 site in Belgium. Open to female participants. Per ClinicalTrials.gov, last updated 2025-01-31.

Sponsored by AgNovos Healthcare, LLC · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started Jul 2021; still recruiting 5 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Not applicable
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies in Osteoporosis with a site in Belgium — 4 open to participants now, 5 under way, none of them phase 3. Osteoporosis · Belgium.

Planned enrollment
17th of 27
150 · median 218
Started
2021
with 1 other
No phase
9 of 32
2 open now
Registered
29th of 32
by date
Lead sponsor
6 of 32
AgNovos Healthcare, LLC

Among the 32 studies in Osteoporosis with a site in Belgium, this one is the 17th largest by planned enrollment of the 27 interventional ones that give a count, is one of 2 that started in 2021, is one of 9 with no phase, and was the 29th registered.

Osteoporosis

1,602 studies on the registry are indexed under Osteoporosis; 209 are open to participants now.

Browse Osteoporosis studies →

Open to participants now

4 of the 32 studies in Osteoporosis with a site in Belgium are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.

This study: female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Osteoporosis with a site in Belgium, or all of them as a file.
02

Study summary

The research will be conducted as a prospective, post-market, multi-center study within Europe. The maximum number of subjects to be treated is 150 across up to 20 sites. This will be a non-randomized and open-label study. The study will collect procedural, short- and long-term data on the safety and clinical performance of AGN1 LOEP in the post-market setting in European countries where AGN1 LOEP is commercially available. AGN1 is intended to form new bone in voids in the proximal femur of women with osteoporosis.

Read the detailed description

To qualify for this study, a subject must have at least one intact hip with bone loss attributable to osteoporosis as indicated by a femoral neck DXA T-score of -2.5 or less.

Follow-up visits will be conducted at 10 days, 42 days, 12 months, and 24 months after the procedure. Study evaluations at each follow-up visit include general health (physical exam and medical history update), VAS pain (not at 10 days), FES-I (not at 10 days), EQ5D-5L and Parker Mobility. A Timed Up and Go Test is performed at the 10-day, 42-day and 12-month follow-up. Patient satisfaction with outcome of surgery will be asked at the 42-day and the 12-month follow-up. DXA scans and X-rays will be performed at 12 and 24 months.

03

Conditions studied

  • Osteoporosis

Keywords

  • Bone mineral density
  • Femoral strength
  • Hip fracture
  • Local osteo-enhancement procedure
  • LOEP
  • proximal femur
  • RECONFIRM
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject is a female (at least 1-year post menses).
  2. Subject has bone loss in the hip attributable to osteoporosis as defined by a femoral neck DXA T-score of -2.5 or less.
  3. Subject has at least one hip without previous surgery or fracture.
  4. Subject is medically stable from any previous treatment or medical procedure in the opinion of the investigator and with an of I or II.
  5. Subject has willingness, ability, and commitment to participate in baseline and follow-up evaluations for the full length of the study.
  6. Subject is capable of giving written to participate in the study.

Exclusion criteria

Exclusion Criteria:

  1. Subject is less than 3 months removed from having a hip fracture repair or prosthesis or elective Total Hip Arthroplasty (THA).
  2. Subject has progressive increase in hip pain over the previous six (6) months that in the opinion of the Investigator suggests moderate to severe intra-articular arthritis, labral tear, extraarticular soft tissue pathology, referred pain, tumor, stress fracture or infection.
  3. Subject is dependent on the use of a wheelchair or is bedridden.
  4. Subject has albumin corrected serum calcium levels outside the normal lab range or has a pre-existing calcium metabolism disorder (e.g., hypercalcemia).
  5. Subject has severe renal insufficiency defined as an estimated (eGFR) \< 30 mL/min or is being treated with dialysis.
  6. Subject has level ≥ 7.5%.
  7. Subject has (BMI) > 35.
  8. Subject exhibits excessive smokeless tobacco use or excessive smoking as determined by the principal investigator*.
  9. Subject is at ASA Class III, IV, V or VI.
  10. Subject exhibits excessive alcohol consumption as determined by the principal investigator*.
  11. Subject has radiological evidence of gross bony or joint pathology of the hip, including signs predictive of atypical femoral fractures (e.g., Cortical beaking) or has been diagnosed and/or treated for atypical femoral fractures.
  12. Subject treated with or systemic glucocorticoids for ten (10) days in the previous six (6) months.
  13. Subject has history of oral or parenteral use of immunesuppressive drugs in the previous twelve months.
  14. Subject has history of metabolic bone disease other than osteoporosis (ex. Paget's disease).
  15. Subject has a history of auto-immune arthritic diseases including rheumatoid, psoriatic, or those associated with systemic lupus erythematosus, spondyloarthropathy, Reiter's Syndrome or Crohn's Disease.
  16. Subject has a history of radiation therapy to the hip or pelvic region.
  17. Subject has a history of any invasive (except basal cell carcinoma), unless treated and with no clinical signs or symptoms of the malignancy for five (5) years.
  18. Subject has known allergies to implanted device.
  19. In the judgement of the Investigator, the subject is not a good study candidate (e.g., inability to maintain follow-up schedule, comorbidity or poor general physical/mental health, or drug or alcohol abuse issues).
  20. Subject is currently enrolled in another clinical study. *AgNovos's recommendation is >1 pack per day smoking and >3 alcoholic drinks per day
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Other
    AGN1 LOEP

    Subjects treated with AGN1 LOEP in proximal femur

    Device: AGN1 LOEP

Interventions

  • DeviceAGN1 LOEP

    Subjects with osteoporosis are treated with AGN1 local osteo-enhancement procedure in the proximal femur

06

What researchers measure

Primary outcomes

  1. Femoral Neck Bone Mineral Density

    6% increase in mean femoral neck BMD from preprocedure baseline to 12 months post-procedure of treated hips

    Time frame: 12 months

  2. Primary Safety Evaluation

    The incidence of all adverse events and serious adverse events occurring post-AGN1 LOEP through the 12 months follow-up period determined to be at least possibly related to the procedure and/or device.

    Time frame: 12 months

Secondary outcomes

  1. Total Hip Bone Mineral Density

    6% increase in mean total hip BMD from preprocedure baseline to 12 months post-procedure of treated hips.

    Time frame: 12 months

  2. Femoral Neck Bone Mineral Density

    6% increase in mean femoral neck BMD from preprocedure baseline to 24 months post-procedure of treated hips.

    Time frame: 24 months

  3. Total Hip Bone Mineral Density

    6% increase in mean total hip BMD from preprocedure baseline to 24 months post-procedure of treated hips.

    Time frame: 24 months

Other outcomes

  1. Bone Formation

    Radiologic appearance of bone formation as assessed by X-ray at 12 and 24 months post-procedure of treated hips.

    Time frame: 12 and 24 months

  2. Patient Satisfaction

    Patient satisfaction with outcome of surgery in the treated hip(s) and overall at 42 days and 12 months assessed with Visual Analogue Scale.

    Time frame: 42 days and 12 months

  3. Pain hip

    Pain (left hip, right hip) at baseline, 42 days, 12 months, and 24 months assessed with Visual Analogue Scale.

    Time frame: baseline, 42 days, 12 months, and 24 months.

  4. Pain body overall

    Pain body overall at baseline, 42 days, 12 months, and 24 months assessed with Visual Analogue Scale.

    Time frame: baseline, 42 days, 12 months, and 24 months.

  5. FES-I

    FES-I at baseline, 42 days, 12 months, and 24 months

    Time frame: baseline, 42 days, 12 months, and 24 months

  6. Quality of Life with EQ5D-5L

    EQ5D-5L at baseline, 10 days, 42 days, 12 months, and 24 months

    Time frame: baseline, 10 days, 42 days, 12 months, and 24 months

  7. Parker Mobility Score

    Parker Mobility Score at baseline, 10 days, 42 days, 12 months, and 24 months.

    Time frame: baseline, 10 days, 42 days, 12 months, and 24 months.

  8. Verifying the enhancement site

    The ability to access the enhancement site by drilling through the lateral femoral cortex of the proximal femur and to determine the boundaries of the enhancement site using the probe debrider.

    Time frame: Procedure (day 0)

  9. Technical Success

    The ability to deliver the necessary amount of AGN1 material to adequately fill the osseous defect as assessed by the treating surgeon.

    Time frame: Procedure (day 0)

  10. SAE

    Incidence of all serious adverse events post-AGN1 LOEP through the 24 months follow-up period.

    Time frame: 24 months

  11. Hip Fracture

    Incidence of new hip fractures on the treated side.

    Time frame: 24 months

  12. Timed up and go test

    Timed up and go test at baseline, 10 days, 42 days and 12 months.

    Time frame: baseline, 10 days, 42 days and 12 months.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2021 (actual). Primary completion is estimated for Dec 2025, 53 months after the start.

Of 239 interventional studies with no phase under Osteoporosis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 50. This study's planned 53 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2021
First posted
Jan 21, 2022
StartActual
Jul 5, 2021
Primary completionEst.
Dec 2025
CompletionEst.
Dec 2026
Last update
Jan 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05202678
Lead sponsor
AgNovos Healthcare, LLC
Responsible party
Sponsor
First posted
Jan 21, 2022
Start date
Jul 5, 2021
Primary completion
Dec 2025 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jan 31, 2025

Study contacts

Adam Lowe
Contact
info@agnovos.com
+1 240 753 6500
Jo De Schepper, MD
principal investigator · AZ Nikolaas

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion